BCRX — BIOCRYST PHARMACEUTICALS INC

Ownership history in Bayesian Capital Management, LP  ·  8 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in BIOCRYST PHARMACEUTICALS INC (BCRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.1% (2022 Q3)
Avg. % of fund
0.04%
First filed
2020 Q1
Last filed
2025 Q3
Quarters held
8
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 17,400 -8,300 -32.3% 0.03% $132K $7.59
2024 Q4 REDUCED 25,700 -17,500 -40.5% 0.02% $193K $7.52
2024 Q2 REDUCED 43,200 -17,400 -28.7% 0.03% $267K $6.18
2023 Q4 REDUCED 60,600 -18,100 -23.0% 0.04% $363K $5.99
4 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BCRX price (monthly, adj. close)

Other funds also holding BCRX

As of 2025 Q4 — sorted by position size

Elmind Capital, LP 4.95% Kynam Capital Management, LP 3Y 4.67% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.43% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.26% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.26% Eversept Partners, LP 3Y 7Y 1.18% RICE HALL JAMES & ASSOCIATES, LLC 3Y 7Y 0.82% DAFNA Capital Management LLC 3Y 7Y 0.76% Parkman Healthcare Partners LLC 3Y 0.67% Vestal Point Capital, LP 0.6%
← Back to Bayesian Capital Management, LP Holdings